HCA Healthcare Inc (Symbol: HCA) shares have surpassed the average analyst 12-month target price of $243.58, trading at $248.88 per share. This movement prompts analysts to consider either downgrading the stock’s valuation or increasing the target price based on underlying business developments. Currently, HCA is covered by 19 analysts, with target estimates ranging from $160 to $286, and a standard deviation of $28.396.
In recent ratings, HCA holds 13 “Strong Buy” recommendations, 2 “Buy” ratings, 2 “Hold” ratings, and 1 “Strong Sell” rating. The overall average rating stands at 1.56, where 1 indicates a “Strong Buy” and 5 denotes a “Strong Sell.” Investors are assessing whether the price of $248.88 is a temporary peak or indicates potential for further appreciation.
